FEP Medical Policy Manual

FEP 2.01.26 Prolotherapy

Effective Date: April 15, 2018

Related Policies:
2.01.16 Recombinant and Autologous Platelet-Derived Growth Factors as a Primary Treatment of Wound Healing and Other Miscellaneous Conditions
6.01.23 Sacroiliac Joint Arthrography and Injection

Prolotherapy

Description
Prolotherapy describes a procedure intended for healing and strengthening ligaments and tendons by injecting an agent that induces inflammation and stimulates endogenous repair mechanisms. Prolotherapy may also be referred to as proliferant injection, prolo, joint sclerotherapy, regenerative injection therapy, growth factor stimulation injection, or nonsurgical tendon, ligament, and joint reconstruction.

FDA REGULATORY STATUS
Sclerosing agents have been approved by the U.S. Food and Drug Administration for use in treating spider and varicose veins. These sclerosing agents include Asclera® (polidocanol), Varithena® (an injectable polidocanol foam), Sotradecol® (sodium tetradecyl sulfate), Ethamolin® (ethanolamine oleate), and Scleromate® (sodium morrhuate). These agents are not currently approved as joint and ligamentous sclerosing agents.

POLICY STATEMENT
Prolotherapy is considered investigational as a treatment of musculoskeletal pain.

BENEFIT APPLICATION
Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

RATIONALE

Summary of Evidence
For individuals who have musculoskeletal pain (eg, chronic neck, back pain), osteoarthritic pain, or tendinopathies of the upper or lower limbs who receive prolotherapy, the evidence includes small randomized trials with inconsistent results. Relevant outcomes are symptoms, functional outcomes, and quality of life. The strongest evidence evaluates the use of prolotherapy for the treatment of osteoarthritis, but the clinical significance of the therapeutic results is uncertain. The evidence is insufficient to determine the effects of the technology on health outcomes.
SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

American Association of Orthopedic Medicine
The American Association of Orthopedic Medicine currently has a recommendation posted online for the use of prolotherapy for back pain. The Association has indicated that “…prolotherapy should be considered a valid treatment option in a selected group of chronic low back pain patients.”

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
The Coverage Issues Manual #35-13 states that prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents are not covered, noting that the medical effectiveness of these therapies has not been verified by scientifically controlled studies. In 1999, on request for reconsideration of coverage for prolotherapy for treatment for chronic low back pain, Medicare retained its noncoverage decision for prolotherapy, citing a lack of scientific evidence on which to base a decision.

REFERENCES
FEP 2.01.26 Prolotherapy


POLICY HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 2011</td>
<td>New Policy</td>
<td>Updated rationale and references, no change in policy statement.</td>
</tr>
<tr>
<td>December 2012</td>
<td>Update Policy</td>
<td>Policy updated with literature review; references 11 and 16 added; reference 20 updated; policy statement unchanged.</td>
</tr>
<tr>
<td>December 2013</td>
<td>Update Policy</td>
<td>Policy updated with literature review adding reference 20. No change to policy statement.</td>
</tr>
<tr>
<td>December 2015</td>
<td>Update Policy</td>
<td>Policy updated with literature review through June 30, 2015; references 12 and 15 added; policy statement unchanged.</td>
</tr>
<tr>
<td>March 2017</td>
<td>Administrative Review</td>
<td>Policy reviewed with no changes.</td>
</tr>
</tbody>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.